The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact

© 2017 European Society of Human Genetics. The International Rare Diseases Research Consortium (IRDiRC) has agreed on IRDiRC Policies and Guidelines, following extensive deliberations and discussions in 2012 and 2013, as a first step towards improving coordination of research efforts worldwide. The...

Full description

Bibliographic Details
Main Authors: Lochmüller, H., TorrentFarnell, J., Le Cam, Y., Jonker, A., Lau, L., Baynam, G., Kaufmann, P., Dawkins, Hugh, Lasko, P., Austin, C., Boycott, K.
Format: Journal Article
Published: Nature Publishing Group 2017
Online Access:http://hdl.handle.net/20.500.11937/73326
_version_ 1848762984790228992
author Lochmüller, H.
TorrentFarnell, J.
Le Cam, Y.
Jonker, A.
Lau, L.
Baynam, G.
Kaufmann, P.
Dawkins, Hugh
Lasko, P.
Austin, C.
Boycott, K.
author_facet Lochmüller, H.
TorrentFarnell, J.
Le Cam, Y.
Jonker, A.
Lau, L.
Baynam, G.
Kaufmann, P.
Dawkins, Hugh
Lasko, P.
Austin, C.
Boycott, K.
author_sort Lochmüller, H.
building Curtin Institutional Repository
collection Online Access
description © 2017 European Society of Human Genetics. The International Rare Diseases Research Consortium (IRDiRC) has agreed on IRDiRC Policies and Guidelines, following extensive deliberations and discussions in 2012 and 2013, as a first step towards improving coordination of research efforts worldwide. The 25 funding members and 3 patient umbrella organizations (as of early 2013) of IRDiRC, a consortium of research funders that focuses on improving diagnosis and therapy for rare disease patients, agreed in Dublin, Ireland in April 2013 on the Policies and Guidelines that emphasize collaboration in rare disease research, the involvement of patients and their representatives in all relevant aspects of research, as well as the sharing of data and resources. The Policies and Guidelines provide guidance on ontologies, diagnostics, biomarkers, patient registries, biobanks, natural history, therapeutics, models, publication, intellectual property, and communication. Most IRDiRC members - currently nearly 50 strong - have since incorporated its policies in their funding calls and some have chosen to exceed the requirements laid out, for instance in relation to data sharing. The IRDiRC Policies and Guidelines are the first, detailed agreement of major public and private funding organizations worldwide to govern rare disease research, and may serve as a template for other areas of international research collaboration. While it is too early to assess their full impact on research productivity and patient benefit, the IRDiRC Policies and Guidelines have already contributed significantly to improving transparency and collaboration in rare disease research.
first_indexed 2025-11-14T10:56:15Z
format Journal Article
id curtin-20.500.11937-73326
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T10:56:15Z
publishDate 2017
publisher Nature Publishing Group
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-733262019-03-21T00:58:27Z The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact Lochmüller, H. TorrentFarnell, J. Le Cam, Y. Jonker, A. Lau, L. Baynam, G. Kaufmann, P. Dawkins, Hugh Lasko, P. Austin, C. Boycott, K. © 2017 European Society of Human Genetics. The International Rare Diseases Research Consortium (IRDiRC) has agreed on IRDiRC Policies and Guidelines, following extensive deliberations and discussions in 2012 and 2013, as a first step towards improving coordination of research efforts worldwide. The 25 funding members and 3 patient umbrella organizations (as of early 2013) of IRDiRC, a consortium of research funders that focuses on improving diagnosis and therapy for rare disease patients, agreed in Dublin, Ireland in April 2013 on the Policies and Guidelines that emphasize collaboration in rare disease research, the involvement of patients and their representatives in all relevant aspects of research, as well as the sharing of data and resources. The Policies and Guidelines provide guidance on ontologies, diagnostics, biomarkers, patient registries, biobanks, natural history, therapeutics, models, publication, intellectual property, and communication. Most IRDiRC members - currently nearly 50 strong - have since incorporated its policies in their funding calls and some have chosen to exceed the requirements laid out, for instance in relation to data sharing. The IRDiRC Policies and Guidelines are the first, detailed agreement of major public and private funding organizations worldwide to govern rare disease research, and may serve as a template for other areas of international research collaboration. While it is too early to assess their full impact on research productivity and patient benefit, the IRDiRC Policies and Guidelines have already contributed significantly to improving transparency and collaboration in rare disease research. 2017 Journal Article http://hdl.handle.net/20.500.11937/73326 10.1038/s41431-017-0008-z Nature Publishing Group restricted
spellingShingle Lochmüller, H.
TorrentFarnell, J.
Le Cam, Y.
Jonker, A.
Lau, L.
Baynam, G.
Kaufmann, P.
Dawkins, Hugh
Lasko, P.
Austin, C.
Boycott, K.
The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact
title The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact
title_full The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact
title_fullStr The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact
title_full_unstemmed The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact
title_short The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact
title_sort international rare diseases research consortium: policies and guidelines to maximize impact
url http://hdl.handle.net/20.500.11937/73326